The objectives of this study were to examine effects of a beta-adrenergic agonist (cimaterol) on growth and muscle development in rabbits and to examine cimaterol's effects on myofibriUar protein degradation (MPD) and on activities of several proteolytic enzymes including the calcium-dependent proteinases (CDP). Twelve New Zealand White rabbits were assigned to either control diets or to diets containing cimaterol for 35 d, after which they were killed and effects on performance and tissue weight gains were determined. Urine was collected from d 21 through 28 from each rabbit for assessment of N~-methylhistidine (NMH) excretion. Cimaterol increased rates of gain, efficiency of gain and skeletal muscle weights. Enhancement in muscle weight was associated with an increase in total DNA and with a reduction in NMH. Cimaterol did not affect activities of cathepsin B, cathepsin D or neutral serine proteinase, but it reduced activities of the millimolar and micromolar forms of the CDP by 58 and 57%, respectively, and it reduced activity of the inhibitor of the CDP (calpastatin) by 52%. Cimaterol-dependent myofibrillar protein accretion was likely mediated, at least in part, by a reduction in MPD. The change in MPD was associated with a reduction in muscle CDP activities. Cimaterol-dependent muscle hypertrophy therefore may involve changes in calcium-dependent proteolysis of myofibrillar proteins. The significance of the effects of cimaterol on calpastatin activity is not known.
Introduction
Control of myofibrillar protein accretion represents the balance between two antagonislpublished as paper number 8738 of the Oregon Agric.
Exp. Sta.
2The authors acknowledge the generous assistance of M. Koohmaraie in development of assays for calcium-dependent proteinases and calpastatin. The authors also thank Helen Chesbrough for typing the manuscript. Cimaterol was a gift of American Cyanamid Co., Princeton, NJ.
Snpported in part by USDA grant 88-37265-3796. t. of Anita. Sci., Oregon State Univ. 5Faculty of Agric., Sana'a Univ,, Sana'a, Yemen Arab Rep~Rblie. eprint requests. Received January 9, 1989 . Accepted April 26, 1989 tic processes, myofibrillar protein synthesis (NIPS) and myofibrillar protein degradation (MPD). Both processes are intensively regulated by endocrine and nutritional status, yet little is known of the enzymatic or molecular control of either. Administration of betaadrenergic agonists to domestic and laboratory animals increases muscle protein accretion in vivo. Emery et al. (1984) and Helferich et al. (1988) reported that these compounds stimulated muscle growth via an effect on protein synthesis, whereas Reeds et al. (1986 Reeds et al. ( , 1988 and Bohorov et al. (1987) reported that anabolic effects were mediated via a reduction in muscle protein degradation. Despite the possibility that MPD may be reduced by betaagonists and that this enhances muscle protein accretion, effects of beta-agonists on MPD 3313 have not been examined directly.
The objective of this study was to investigate effects of cimaterol on urinary N xmethylhistidine (NMH) excretion in growing rabbits to examine the hypothesis that betaadrenergic agonist-dependent skeletal muscle hypertrophy is mediated by a reduction in MPD. Where alterations in MPD were indicated, a secondary objective was to employ this as a model in which control of degradation could be studied. Accordingly, we examined the relationships between cimaterol-dependent alterations in NMH with activities of cathepsin B, cathepsin D, neutral serine proteinase, miilimolar and micromolar forms of calciumdependent proteinases and the inhibitor of the calcium-dependent proteinases, calpastatin.
Materials and Methods
Twelve male New Zealand White rabbits, weighing approximately 935 g each, were 7Virtus, Gardiner, New York. SPITC, Pierce Chemical Co., Rockford, IL. 9TEA, Aldrich Chemical Co., Milwaukee, WI. 10Waters Associates, Milford, MA.
obtained from the Oregon State University Rabbit Research Center and equal numbers (n = 6) were assigned randomly to each of two experimental pelleted diets (Table 1) . These consisted of a control diet and this diet with added cimaterol (10 mg/kg). Calculated crude protein and digestible energy contents of these diets were 16% and 2,850 Mcal/kg, respectively. Animals were housed in individual hanging cages for a 35-d feeding trial during which feed and water were available ad libitum. Feed intakes and weight gains were monitored weekly. On d 21 through d 28-of the trial, animals were placed in individual stainless steel metabolic cages for collection of urine into 4 ml of 5 N HCI. Ten percent of each day's urine output was retained and frozen. At the end of the collection period, urine samples from each animal were pooled and an aliquot was taken for determination of urinary NMH concentrations.
On the 35th d of the study, animals were killed by cervical dislocation and exsanguination and were rapidly skinned and eviscerated. The carcass was weighed, and liver, heart, kidneys, biceps femoris, extensor digitorum longus (EDL), gastrocnemius, semitendinosus, semimembranosus, triceps bracheii, soleus and plantaris were removed, weighed and frozen between blocks of dry ice. Tissue samples were stored frozen at -80~ wrapped in aluminum foil and plastic, until assay of their constituents.
RNA and DNA Concentrations. Muscle and liver DNA contents were determined using Hoerscht dye 33258 (LaBarca and Paigen, 1980) . RNA contents in tissues were determined (Monro and Fleck, 1969) . Urinary N~-methylhistidine Determination.
Samples of urine (2 ml) were heated to 100*C for 2 h with 2 ml 4 N HCI to deacetylate NMH. Samples of deacetylated urine (.5 ml) were lyophilized in a Virtus Uni-Top 7 Model 600 SL freezer dryer, then resuspended and derivatized as phenylisothiocyanate (PITC) 8 derivatives wtth .5 ml of a 7:1:1:1 mixture of ethanol:PITC8:TEA9:water. Samples stood at room temperature for 20 rain and then were lyophilized and resuspended in .5 ml of 5 mM phosphate buffer (pH 6.5) in 5% (v/v) acetonitrile. Within 6 h of resuspension in diluent, samples (.2 ml) were analyzed by HPLC 10 for total PITC-NMH content. Samples were injected onto a Pico-Tag 10 15-cm HPLC column using a Model 710B sample injector ~~ and a Activity of the heat-stable inhibitor of the CDP (calpastatin) also was determined. All assays were conducted during periods of time during which reactions were linear. Cathepsins B and D and NSP activities were determined using triplicates with duplicate zero-time controls. Cathepsin B activity in EDL was determined according to the method of Rodemann et al. (1983) . Briefly, samples of muscle were homogenized in 9 vol of a buffer consisting of 155 mM KH2PO4, 4.5 mM citric acid, 4 ml EDTA (pH 6.0) and 40 ktl of homogenate combined with 250 ~tl of 2 mM dithiothreitol (DTT), 170 ~tl water and 40 gl of CBZ-alanylarginyl-arginyl-MNA 12 such that final substrate concentration was 5 raM. Samples were llEluents 1 and 2 were obtained from Waters Associates, Milford, MA. Catalog numbers are 10960 and 10965, res it~2 tively 9
Enzymes Systems Products, Livermore, CA. 13SLM Aminco Model II fluorocolorirneter. 14Bachem Fine Chemicals, Torrance, CA.
incubated for 2 h at 37~ and the reaction was stopped with 2 ml 1N HC1. Samples then were centrifuged at 1,000 x g for 10 rain and the fluorescence of the released [~-naphthylamine in the supematant fluid (excitation 292 run, emission 410 nm) was examined with a fluorocolorimeter 13.
Cathepsin D activity in plantaris was determined according to the method of Takahashi and Tang (1981) using bovine hemoglobin as a substrate. Samples were incubated for 20 rain. Neutral serine proteinase (NSP) activity in 1 g of biceps femoris was determined according to methods of Kar and Pearson (1980) using Z-glycyl-glycyl-arginylNNap 14 at 2.5 mM as a synthetic substrate. Neutral serine proteinase-dependent release of ~-naphthylamine from this substrate was examined as described for cathepsin B. Incubations were for 3 h.
Biceps femoris, gastrocnemius and semimembranosus muscles were combined for assay of the activities of ktCDP, mCDP and calpastatin. The method of Koohmaraie et al. (1989) was used for these assays, except for minor modifications. Thawed muscle samples (50 to 60 g) were minced and homogenized in 2.5 vol of extraction buffer (100 mM Tris, 10 mM [~-mercaptoethanol (MCE), 5 mM EDTA (pH 8.3) in a Waring blender. Each sample was homogenized three times for 30 s with 30 s cooling between each burst. Samples were centrifuged at 25,000 x gmax for 90 min and the supernatant fluid was filtered through cheesecloth and then glass wool and adjusted to pH 7.5. Each sample was dialyzed at 4~ in a Spectrapor dialysis bag 15 (12,000 molecular weight cut-off) for 24 h against four changes of 20 mM Tris, 5 mM EDTA, 10 mM MCE (pH 7.5) and centrifuged at 25,000 x gmax for 1 h. Volume and protein concentration of the supernatant fluid (Bradford, 1976) were determined. The sample was loaded onto a 16-x 200-mm DEAE-Sephace116 column with an Isco 17 Wiz pump at 10 ml/h and was washed with elution buffer (20 mM Tris, .1 mM EDTA, 10 mM MCE, pH 7.35) until Abs280 of column eluent fell below .400. After this, a gradient of 0 to 300 mM NaCI in elution buffer (1:1) was applied at 30 ml/h such that 100 fractions of 10 ml each were collected with an Isco 17 fraction collector over a period of 33.3 h. Column conditions were regenerated prior to loading of subsequent samples by washing it with elution buffer containing 1 M NaCI until Abs280 of the eluent was nondetectable (approximately 6 h) and then washing the column with elution buffer containing 0 mM NaCI for 6 h to regenerate initial conditions. Activity of txCDP in individual fractions was examined by measuring the degradation of casein 18 in the presence and absence of calcium (Ca ++ ) in assay media. Samples of eluents (.5 ml) were combined with 1.5 ml of Ca++ assay media (100 mM "Iris, 5 mM DTI', 1 mM NAN3, 5 lxM CaCI2, 5 mg/ml casein 18, pH 7.5) or with 1.5 ml of EDTA assay media lSHammarsten casein, U.S. Biochemical Corp., Cleveland, OH.
19Shimadzu Corp., Kyoto, Japan.
(5 mM EDTA replaced CaCI 2 in Ca++-assay medium) and incubated for 30 min at 25~ Reaction was stopped by addition of 2.0 ml 5% trichloroacetic acid (TCA) and samples were allowed to stand for 4"C for several hours. Samples were centrifuged for 10 min at 3,000 x g and then Abs280 of the supernatant fluid was determined using a Shimadzu 19 Model UV-160 spectrophotometer. The difference in Abs280 between Ca++-vs EDTA-assay media was used to estimate the Ca++-dependent proteolysis. Activity of mCDP was determined as described above except that 5 mM CaC12 was included in Ca ++ assay medium.
Assay of Calpastatin. Calpastatin activity was determined according to the method of Koohmaraie et al. (1989) . Fractions containing mCDP activity from various assays were pooled and stored at -80"C. Individual column fractions were heated at 90"C for 3 min to remove residual proteolytic activity and centrifuged at 2,000 x g for 30 min. Calpastatin activity was determined at 25*C for 30 min by combining. 1 ml of eluents with 1.5 ml Ca ++-assay media and .5 ml of mCDP stock and comparing casein hydrolysis to a control tube in which water replaced the sample of heattreated column eluent. Units of calpastatin activity are expressed on a milligram protein basis (Bradford, 1976) .
Statistical Analyses. For comparisons between control-fed and cimaterol-fed animals we used a Student's t-test (Steel and Torrie, 1980) . A significance level of 5% was adopted for all comparisons.
Results
The effects of cimaterol on rabbit performance are shown in Table 3 . Cimaterol stimulated weight gains (P < .05) 27% and increased feed intake 6.9% (P < .05). Efficiency of gain was improved 18.9% (P < .05). Dressed carcass weight and percent dressed weight also were increased by cimaterol (P <
.05).
Cimaterol did not affect liver and kidney weights, but heart weight and weights of various skeletal muscles were increased (P < .05; Table 4 ). The effect of cimaterol on heart weight disappeared when heart weight was expressed as a proportion of final body weight (data not shown); however, skeletal muscle weights, expressed on this basis, were increased by cimaterol (Table 4) .
Cimaterol did not affect liver DNA or RNA concentrations or the RNA/DNA ratio. Cimaterol did not affect (P > .05) DNA concentration in biceps femoris, EDL or gastrocnemius; however, in each tissue there was a tendency for cimaterol to increase DNA concentration. Because muscle size was increased by cimaterol, total DNA content in each of these muscles was increased 53 to 77% (P < .05). RNA concentration was elevated in muscles of cimaterol-treated rabbits; however, only in gastrocnemius was this increase significant (P < .05). Total RNA content was increased (P < .05) in all muscles sampled. The ratio of RNA to DNA was decreased by cimaterol in biceps femoris (P < .05) but not in EDL or gastrocnemius.
Cimaterol reduced urinary NMH excretion 17.8% (P < .05; Table 5 ); however, when a,bValues are means + SEM. Values in the same row with different superscripts differ significantly (P < .05). Due to limitations in tissue quantifies, not all assays were conducted using the same muscle source. Activities of ~tCDP, mCDP and calpastatin were determined using combined biceps femoris, gastrochemius and semimembranosus. Cathepsin B activity was determined in EDL, and cathepsin D activity in plantaris. NSP activity was determined in biceps femoris.
CCathepsin B and NSP 4 activities are expressed as nmoles of ~l-naphthylamine released from their respective synthetic peptides/(mg tissue.min).
dCathepsin D activity is expressed as Abs2$0/g tissue/20 rain using hemoglobin as a substrate.
~lculral scrinc proteinasc.
fMicromolar form of calcium-dependcm protcasc (mU/mg protein). One unit of laCDP will produce a Abs278 of.5 in 30 rain at pH 7.5 at 25"C measured as Irichloroacetic acid (TCA)-soluble products using casein as a substrate. For both treatmerits two samples were lost due to inadequate separation of ~tCDP and calpastatin. Hence, values reported here are the mean of four animals on both control and cimaterol-fed treatments. gMillimolar form of calcium-dependent proteasc (mU/mg protein). One unit of mCDP will produce a Abs27 $ of .5 in 30 rain at pH 7.5 at 25"C measured as TCA soluble-products using casein as a substrata and 5 mM CaCI 2 in assay me.dium.
hCalcium-dependent proteinase inhibitor (calpastatin, mURag protein). One unit of calpastatin will reduce the activity of one unit of mCDP by 50% at pH 7.5 at 25"C.
urinary NMH excretion was expressed as a proportion of body weight, NMH excretion was reduced 28.4% (P < .05), Because betaadrenergic agonists increase muscle as a proportion of body weight, reduction of NMH excretion per unit muscle mass probably was greater than indicated by expression of NMH excretion on a body weight basis.
Micromolar CDP activity eluted from the DEAE-Sephacel column immediately following elution of calpastatin. The millimolar form of CDP was resolved easily from both calpastatin and laCDP. Occasionally, small quantities of additional calpastatin activity eluted following ~tCDP; however, appearance of this was not treatment-dependent. Whether this was a processed form or catabolite of calpastatin was not examined.
Cimaterol reduced (P < .005) activities of both laCDP and mCDP 58 and 57%, respectively. Activity of the major calpastatin peak also was reduced (P < .001) 52% by dietary cimaterol. Activities of cathepsin B, cathepsin D and NSP were not affected by cimaterol (P > .05, Table 5 ).
Disoulmion
Cimaterol exerted its characteristic growthpromoting actions in rabbits similar to those reported previously in a variety of species including rats (Emery et al., 1984; Reeds et al., 1986 Reeds et al., , 1988 Maltin et al., 1986 Maltin et al., , 1987 Zeman et al., 1987) , chickens , beef cattle , sheep (Beermann et al., 1986; Wilson et al., 1988) and pigs Moser et al., 1984) . The 27% improvement in gain caused by cimaterol was not mediated by a large increase in feed intake. Rather, increased efficiency of gain accounted largely for cimaterol's growthpromoting actions.
The mechanisms by which cimaterol and other beta-adrenergic agonists stimulate muscle protein accretion in vivo have been examined previously. Emery et al. (1984) reported that clenbuterol increased muscle protein synthesis in growing rats and Helferich et al. (1988) reported that ractopamine increased muscle alpha-actin biosynthesis in swine.
Other investigators Bohorov et al., 1987) , however, found no effects of clenbuterol on muscle protein synthesis in rats and sheep, respectively, and concluded that beta-agonist-dependent muscle growth promotion was mediated by a reduction in muscle protein degradation. The present study provides more direct support to this possibility.
The RNA/DNA ratio and RNA concentration have been used as estimates of protein synthetic capacity of tissues Beermann et al., 1987) . The RNA/DNA ratio either was not affected by cimaterol or, in biceps femoris, it was reduced. Hence, we have no evidence supporting the concept that protein synthesis per unit DNA was increased by cimaterol.
Other investigators have reported that betaagonists increased skeletal muscle RNA content (Maltin et al., 1986 (Maltin et al., , 1987 Reeds et al., 1986; Beermann et al., 1987) and did not affect DNA content (Beermann et al., 1987; Kim et al., 1987; Reeds et al., 1988) . In this study cimaterol increased total muscle RNA, RNA concentration in gastrocnemius and DNA contents. The latter observation suggests that either cimaterol promotes satellite cells' conlribution of DNA to existing muscle cells or it causes proliferation of other cell types associated with muscle. The reasons for the disagreement between our observation of DNA contents and other studies are not known. Increased RNA content and concentration implies net protein synthesis may be increased; however, estimates of protein synthesis per unit RNA, needed to confirm this possibility, were not conducted in this study.
To gain an understanding of the enzymatic basis by which cimaterol reduced NMH, we assessed its effects on activities of a variety of proteolytic enzymes. These included the calcium-dependent proteinases, which are believed to initiate degradation of myofibfillar proteins in vivo (Dayton et al., 1976a,b; Dayton and Schollmeyer, 1980) , neutral serine proteinase, which has been implicated in human myopathic disorders (Kar and Pearson, 1980) , and two lysosomal cathepsins. The lysosomal enzymes may be unlikely targets for regulation of MPD; however, they have been implicated in sarcoplasmic protein degradation (Bird et al., 1980; Goldspink and Lewis, 1985) . Recent evidence supports the belief that lysosomes play an important role in degradation of muscle proteins (Gerard et al., 1988) , although it is not clear which proteins are substrates for lysosomal proteolysis. We also were interested in determining whether coordinate regulation of CDP, NSP and cathepsins existed.
Activities of the cathepsins and NSP were not affected by cimaterol. However, activities of IxCDP, mCDP and calpastatin were reduced. This suggests that regulation of calciumdependent proteolysis may be a mechanism by which cimaterol regulates MPD. The similarity in response of ktCDP, mCDP and calpastatin to cimaterol treatment suggests coordinate regulation. Higgins et al. (1988) reported that clenbuterol increased calpastatin and MCDP activities and reduced ~tCDP activity in sheep muscle. Wang and Beermann (1988) reported that cimaterol reduced lxCDP activity but increased total CDP activity in muscle tissue taken from lambs. This implies that activity of mCDP was increased in their animals. Contrary to these studies, we observed a reduction in mCDP activity.
Although changes in total CDP activity indicate involvement of CDP in cimateroldependent muscle hypertrophy, several aspects of their regulation require further examination. First, measurement of CDP activity reflects potential CDP activity because activities were determined in the presence of saturating Ca ++ concentrations, because CDP are physically separated from calpastatin prior to asSay and because autolytic activation of CDP during the purification process may occur (Suzuki et al., 1988) . Artifactual autolytic activation is a concern in assaying CDP activities because Nagainis et al. (1988) have reported that mCDP exists almost entirely in the unautolyzed form in situ. The compartments in which activity is expressed were not determined in these studies. In addition, it still is not known which of the two CDP, or whether both, have activity at the myofibril.
Calpastatin plays a central role in regulation of CDP activity in cells (Suzuki et al., 1988) . It inhibits translocation of CDP to membranes, removes both inactive and active forms of CDP from membranes and inhibits autolytic activation of CDP (Suzuki et al., 1988) . Calpastatin usually is found within the same metabolic compartment as the CDP. Hence, the significance of our observation that cimaterol reduced calpastatin activity is difficult to interpret because it is associated with reduced CDP activity. Despite this reduction, total muscle calpastatin activity remained sufficient to completely inhibit total tissue CDP activity. This also has been reported by Gopalakrishna and Barsky (1986) . These authors, however, reported that association of CDP with substrate in cellular particulate fractions reduced susceptibility of CDP to inhibition because calpastatin activity was located primarily in nonparticulate fractions. Hence, stoichiometric excess of calpastatin activity may not preclude Ca ++-dependent digestion of myofibrillar proteins and instead may prevent indiscriminate Ca + § dependent digestion of sarcoplasmic proteins. Kapprell and Goll (1989) reported that lxCDP may be not so sensitive to inhibition by calpastatin as mCDP is; hence, digestion of myofibrillar proteins by ~tCDP may occur despite the excess of calpastatin. The possibility that ~tCDP may be of greater significance to degradation of myofibrillar proteins than mCDP also is indicated by the observation of Kapprell and Goll (1989) , who reported that autolyzed I.tCDP required less Ca ++ for its activation than autolyzed mCDP, and by the observations of Suzuki et al. (1988) , who reported that mCDP, but not lxCDP, required translocation to membranes for its activation.
This study indicates that cimaterol slimulates muscle growth by reducing myofibrillar protein degradation. Control of CDP activities has been implicated in cimaterol-dependent muscle hypertrophy; however, several aspects of the regulation of these enzymes need to be clarified. First, most CDP activity exists in a non-myofibrillar compartment (Ishiura, 1980), and it is not known whether changes in total tissue CDP activity are representative of activity expressed within the myofibriUar compartment. Second, although this study implicates both CDP in control of myofibrillar protein degradation, it remains unknown whether IxCDP, mCDP or both enzymes degrade myofibrillar proteins in vivo. Third, the significance of caipastatin and changes in its activity to control of degradation of myofibrillar proteins needs to be resolved. Finally, ATP-dependent proteinases have been found in skeletal muscle (Fagan et ai., 1987) . In a review article Kettelhut et al. (1988) suggested that this proteolytic mechanism is important to degradation of myofibrillar proteins and that the significance of CDP to this process is limited. Future studies will need to evaluate the relative roles of these and possibly other proteinases to degradation of muscle proteins.
